Rates and Influences of Alcohol Use Disorder Comorbidity among Primary Stimulant Misusing Treatment-Seekers: Meta-analytic Findings Across Eight NIDA CTN Trials

REFERENCES

• SAMHSA. National Household Survey on Drug Abuse: Population estimates, 1994; 1995.
   Google Scholar
• UNODU S. 2008 World Drug Report. Vienna, Austria; 2008.
   Google Scholar
• OA S. Results from the 2006 National Survey on Drug Use and Health: National findings. Rockville, MD; 2008. Report No.: DHHS Publication #SMA 07-4293.
   Google Scholar
• Copeland AL, Sorenson JL. Differences between methamphetamine users and cocaine users in treatment. Drug and Alcohol Dependence 2001; 62:91–95.
   PubMed Web of Science ®Google Scholar
• Huber A, Ling W, Shoptaw S, Gulati V, Blethen P, Rawson R. Integrating treatments for methamphetamine abuse: A psychosocial perspective. Journal of Addictive Diseases 1997; 16:41–50.
   PubMed Web of Science ®Google Scholar
• Luchansky B, Krupski A, Stark K. Treatment response by primary drug of abuse: Does methamphetamine make a difference? Journal of Substance Abuse Treatment 2007; 32:89–96.
   PubMed Web of Science ®Google Scholar
• Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, Schwartz M, Krasnansky J, Pencer E, Silva-Vasquez L, Kirby K, Royer-Malvestuto C, Roll JM, Cohen A, Copersino ML, Kolodner K, Rui L. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network Study. Archives of General Psychiatry 2006; 63(2):201–208.
   PubMed Web of Science ®Google Scholar
• Petry NM, Peirce J, Stitzer ML, Blaine J, Roll JM, Cohen A, Obert J, Killeen T, Saladin ME, Cowell M, Kirby KC, Sterling R, Royer-Malvestuto C, Hamilton J, Booth RE, Macdonald M, Liebert M, Rader L, Burns R, DiMaria J, Copersino M, Stabile PQ, Kolodner K, Li R. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A national drug abuse treatment clinical trials network study. Archives of General Psychiatry 2005; 62(1148–1156).
   PubMed Web of Science ®Google Scholar
• Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. New York, NY: Springer; 1998.
   Google Scholar
• Tai B, Straus MM, Liu D, Jackson R, McCarty DJ. The first decade of the National Institute on Drug Abuse Clinical Trials Network: Bridging the gap between research and practice to improve drug abuse treatment. Journal of Substance Abuse Treatment 2010; 38(Supplement 1):S4–S13.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Cacciola J, Griffith JE. New data from the Addiction Severity Index: Reliability and validity from three centers. Journal of Nervous and Mental Disease 1985; 173:412–423.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinatti H, Argeriou M. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992; 9:199–213.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. Journal of Nervous and Mental Disease 1980; 168:26–33.
   PubMed Web of Science ®Google Scholar
• Hartzler B, Donovan DM, Huang Z. Comparison of opiate-primary treatment-seekers with and without alcohol use disorder. Journal of Substance Abuse Treatment 2010; 39(2): 114–123.
   PubMed Web of Science ®Google Scholar
• Miele GM, Carpenter KM, Smith-Cockerham M, Dietz-Trautman K, Blaine J, Hasin DS. Concurrent and predictive validity of the Substance Dependence Severity Scale. Drug and Alcohol Dependence 2000; 59(1):77–88.
   PubMed Web of Science ®Google Scholar
• Hudziak JJ, Helzer JE, Wetzel MW, Kessel KB, McGee B, Janca A, Pryzbeck T. The use of the DSM-III-R Checklist for initial diagnostic assessments. Comparative Psychiatry 1993; 34(6):375–383.
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 1994; 51(1):8–19.
   PubMed Web of Science ®Google Scholar
• Hedges L, Olkin I. Statistical methods for meta-analysis. Orlando, FL: Academic Press; 1985.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7:177–188.
   PubMedGoogle Scholar
• Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. West Sussex, UK: John Wiley & Sons, Ltd.; 2009.
   Google Scholar
• Brooks A, Meade CS, Sharpe-Potter J, Lokhnygina Y, Calsyn DA, Greenfield SF. Gender differences in the rates and correlates of HIV risk behaviors among drug abusers. Substance Use and Misuse in press.
   Google Scholar
• Alterman AI, McKay JR, Mulvaney FD, Cnaan A, Cacciola J, Tourian KA, Rutherford MJ, Merikle EP. Baseline prediction of 7-month cocaine abstinence for cocaine-dependent patients. Drug and Alcohol Dependence 2000; 59(3):215–221.
   PubMed Web of Science ®Google Scholar
• Forman RF, Svikis DS, Montoya ID, Blaine J. Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2004; 27(1):1–8.
   PubMed Web of Science ®Google Scholar
• Wells EA, Saxon AJ, Calsyn DA, Jackson TR, Donovan DM. Study results from the Clinical Trials Network's first 10 years: Where do they lead? Journal of Substance Abuse Treatment 2010; 38(Supplement 1):S14–S30.
   PubMed Web of Science ®Google Scholar